| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
CTNM
Contineum Therapeutics, Inc. Class A
|
Sep 15, 2026 | BUY |
Strong Buy
+58.6% avg upside
9 analysts
|
$19.00
40.34% Upside
|
+0.1% | · |
|
DNLI
Denali Therapeutics
|
Aug 07, 2026 | BUY |
Strong Buy
+96.4% avg upside
24 analysts
|
$34.00
72.35% Upside
|
-14.5% | · |
|
DRUG
Bright Minds Biosciences
|
Feb 13, 2026 | BUY |
Strong Buy
+119.7% avg upside
10 analysts
|
$126.00
106.54% Upside
|
-21.7% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.